-

06:40:47 PM

FWBI Stock News

FWBI - First Wave BioPharma Inc

01/31/23 7:00 AM

Nasdaq : FWBI

clinical triallow float

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted,

RHEA-AI

neutral

01/30/23 7:00 AM

Nasdaq : FWBI

conferenceslow float

First Wave BioPharma to Present at the BIO CEO & Investor Conference

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced

RHEA-AI

neutral

01/25/23 7:00 AM

Nasdaq : FWBI

low float

First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced

RHEA-AI

neutral

01/24/23 7:00 AM

Nasdaq : FWBI

conferenceslow float

First Wave BioPharma to Present at Sequire Biotechnology Conference

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced

RHEA-AI

neutral

01/13/23 4:00 PM

Nasdaq : FWBI

clinical triallow float

First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that

RHEA-AI

neutral

01/13/23 10:20 AM

Nasdaq : FWBI

low float

First Wave BioPharma Announces Results of Special Meeting of Stockholders

First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today

RHEA-AI

neutral

01/09/23 9:10 AM

Nasdaq : FWBI

low float

First Wave BioPharma Announces Adjournment of Special Meeting

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today

RHEA-AI

neutral

01/05/23 9:45 AM

Nasdaq : FWBI, ZVSA

managementlow float

ZyVersa Therapeutics Appoints Three New Board Members

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage

RHEA-AI

neutral

12/12/22 7:30 AM

Nasdaq : FWBI

conferenceslow float

First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”

First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced

RHEA-AI

neutral

12/05/22 7:00 AM

Nasdaq : FWBI

clinical triallow float

First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies

RHEA-AI

neutral

1 2 3 4 5 6 Next

FWBI Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.firstwavebio.com
CeoJames Sapirstein
Security nameFirst Wave BioPharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Address760 Parkside Ave Ste 304
StateNew York
CityBrooklyn
Zip11226-1784
CountryUS
Phone16466997855

About First Wave BioPharma Inc

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. First Wave’s niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS); and FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis (ICI-AC) and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (for ulcerative colitis) and FW-CD (for Crohn’s disease) are expected to enter the clinic in 2022 and 2023, respectively. First Wave is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California.